The global pharmaceutical sector is embarking on a transformational journey in which the supply chain will play an increasing strategic role. There will be a need for greater agility and improved speed to market – while ensuring compliance with myriad regulatory requirements in countries – forming a challenging landscape for the global pharma industry.
One of the drivers of this change is the merger and acquisition (M&A) activity in the industry. According to PricewaterhouseCoopers, M&A activity in the pharmaceutical sector surged in the second quarter of this year with 62 deals announced representing almost $170 billion of total value.
Click here to download the full WhitePaper